1. Bastain, T.M., T. Islam, K.T. Berhane, R.S. McConnell, E.B. Rappaport, M.T. Salam, W.S. Linn, E.L. Avol, Y. Zhang, and F.D. Gilliland,
Exhaled nitric oxide, susceptibility and new-onset asthma in the Children's Health Study. Eur Respir J, 2011. 37(3): p. 523-31.
Comment: This article demonstrates the value of FENO in predicting new-onset of asthma in children.
2. Bukstein, D., A.T. Luskin, and E.A. Brooks,
Exhaled nitric oxide as a tool in managing and monitoring difficult-to-treat asthma. Allergy Asthma Proc, 2011. 32(3): p. 185-92.
Comment: In this study, the cost savings by using FENO as an asthma management or monitoring tool in severe asthmatics are demonstrated.
3. Corren, J., R.F. Lemanske, N.A. Hanania, P.E. Korenblat, M.V. Parsey, J.R. Arron, J.M. Harris, H. Scheerens, L.C. Wu, Z. Su, S. Mosesova, M.D. Eisner, S.P. Bohen, and J.G. Matthews,
Lebrikizumab Treatment in Adults with Asthma. N Engl J Med, 2011 365(12):1088-98.
Comment: Serum periostin is used to find patients that respond to treatment with lebrikizumab. In a post-hoc analysis they find that FeNO is at least as good as periostin to find such patients.
4. Dweik, R.A., P.B. Boggs, S.C. Erzurum, C.G. Irvin, M.W. Leigh, J.O. Lundberg, A.C. Olin, A.L. Plummer, and D.R. Taylor,
An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric oxide Levels (FENO) for Clinical Applications. Am J Respir Crit Care Med, 2011. 184(5): p. 602-615.
Comment: The ATS guideline published in September recommends FENO measurements for assessing and monitoring airway inflammation as well as identifying patients responsive to corticosteroids. Further, FENO is recommended for identifying non-adherence to ICS treatment.
5. Garriga, T., M. Labrador-Horrillo, M. Guillen, O. Luengo, J.L. Eseverri, M. Guilarte, A.M. Marin, and V. Cardona,
Spirometric Maneuvers and Inhaled Salbutamol Do Not Affect Exhaled Nitric oxide Measurements among Patients with Allergic Asthma. Respiration, 2011. (not in print yet)
Comment: Garriga et al show that neither spirometry nor beta-2 agonist treatment prior to FENO measurements (using NIOX MINO) affects the resulting values.
6. Hozawa, S., M. Terada, and M. Hozawa, Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma. Pulm Pharmacol Ther, 2011. 24(5):571-6.
Comment: This clinical study demonstrates that FENO can be used to differentiate between two ICS/LABA combination treatments.
7. Kalliola, S., P. Malmberg, T. Rito, A.S. Pelkonen, and M.J. Makela, Can we use portable nitric oxide analyzer in young children? Pediatr Pulmonol, 2011. 46(7): p. 627-31.
Comment: Kalliola et al have successfully used NIOX MINO for FENO measurements in children from the age of 4 (success rate 73%) with significant differences shown between asthmatics and healthy controls.
8. Koster, E.S., J.A. Raaijmakers, S.J. Vijverberg, and A.H. Maitland-van der Zee,
Inhaled corticosteroid adherence in paediatric patients: the PACMAN cohort study. Pharmacoepidemiol Drug Saf, 2011. 20(10): p. 1064-72.
Comment: This study shows a correlation between high FENO levels and low adherence in children using ICSs. NIOX MINO was used in this study.
9. Ozier, A., P.O. Girodet, I. Bara, J.M. Tunon de Lara, R. Marthan, and P. Berger,
Control maintenance can be predicted by exhaled NO monitoring in asthmatic patients. Respir Med, 2011. 105(7): p. 989-96.
Comment: FENO measurements, using NIOX MINO or a competitor device, are shown to predict the persistence of asthma control in well controlled patients.
10. Powell, H., V.E. Murphy, D.R. Taylor, M.J. Hensley, K. McCaffery, W. Giles, V.L. Clifton, and P.G. Gibson, Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet, 2011. 378(9795): p. 983-90.
Comment: In this Lancet paper, FENO measurements were used to guide ICS treatment in pregnant women. The FENO guided group had a significantly lower exacerbation rate compared to healthy controls and experienced an improvement in quality of life.
11. Sardon Prado, O., E.G. Perez-Yarza, A. Aldasoro Ruiz, J. Korta Murua, P. Corcuera Elosegui, J. Mintegui Aramburu, and J.I. Emparanza Knorr,
Fraction of Exhaled Nitric oxide and Asthma Predictive Index in Infants Less Than Two Years-Old. Arch Bronconeumol, 2011. 47(5): p. 234-238.
Comment: High FENO values in children <2 years of age (obtained using a tidal breathing technique) are correlated to a positive asthma predictive index.
12. Szefler, S.J.,
Personalised medicine for asthma management in pregnancy. Lancet, 2011. 378(9795): p. 963-4.
Comment: This letter comment’s the study by Powell et al in the same Lancet issue.
13. Taylor, D.R., R. Palmay, J.O. Cowan, and G.P. Herbison,
Long term performance characteristics of an electrochemical nitric oxide analyser. Respir Med, 2011. 105(2): p. 211-7.
Comment: This study demonstrates long term reproducibility of the NIOX MINO device in a clinical setting.
14. Wang, L., C.S. Hollenbeak, D.T. Mauger, R.S. Zeiger, I.M. Paul, C.A. Sorkness, R.F. Lemanske, Jr., F.D. Martinez, R.C. Strunk, S.J. Szefler, and L.M. Taussig, Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial. J Allergy Clin Immunol, 2011. 127(1): p. 161-6, 166 e1.
Comment: FENO, as a measure of inflammation, is here used to prove the superior effectiveness of ICS treatment vs anti-leukotriene treatment in children with mild-to-moderate asthma.
15. Zeiger, R.S., M. Schatz, F. Zhang, W.W. Crawford, M.S. Kaplan, R.M. Roth, and W. Chen,
Association of exhaled nitric oxide to asthma burden in asthmatics on inhaled corticosteroids. J Asthma, 2011. 48(1): p. 8-17.
Comment: FENO (here measured using NIOX MINO), is recommended to be a complementary tool for assessment of asthma burden.
17. Zeiger, R.S., M. Schatz, F. Zhang, W.W. Crawford, M.S. Kaplan, R.M. Roth, and W. Chen, Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids. J Allergy Clin Immunol, 2011. 128(2): p. 412-4.
Comment: In this letter to the editor, Zeiger et al states that FENO determination is clinically useful in identifying patients on ICS at risk for future uncontrolled asthma, based on an analysis of the study by Zeiger et al published in J of Asthma (see above).